TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29941012

Group type: EXPERIMENTAL
Intervention: Jugular vein catheterization
Number of subjects: 160

Group type: COMPARATOR
Intervention: Femoral vein catheterization
Number of subjects: 160
Study: 29941024

Group type: EXPERIMENTAL
Intervention: Standard physical education curriculum (60 min/week, low-to-moderate intensity)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-intensity physical education curriculum (HIPE, 60 min/session, 3 times/week, 300-500 kcal/session at 75-85% HRmax)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low-to-moderate intensity physical education curriculum (LIPE, 60 min/session, 3 times/week, 300 kcal/session at 55-75% HRmax)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined HIPE and LIPE curriculum (60 min/session, 3 times/week)
Number of subjects: 100
Study: 29941047

Group type: EXPERIMENTAL
Intervention: Naproxen/Esomeprazole (NAP/ESO)
Number of subjects: 46
Study: 29941235

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle program
Number of subjects: 779
Study: 29941289

Group type: EXPERIMENTAL
Intervention: Completion pancreatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 29941458

Group type: EXPERIMENTAL
Intervention: New risk stratification system
Number of subjects: 0
Study: 29941469

Group type: EXPERIMENTAL
Intervention: Siemens-hs-cTnI-Centaur
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Roche-hs-cTnT-Elecsys
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Abbott-hs-cTnI-Architect
Number of subjects: 1755
Study: 29941496

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29941707

Group type: EXPERIMENTAL
Intervention: Pelvic exenteration (PE)
Number of subjects: 38
Study: 29942123

Group type: EXPERIMENTAL
Intervention: CAPTURE assessment (5 questions and PEF thresholds)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: mMRC dyspnea scale and CAT™
Number of subjects: 73
Study: 29942272

Group type: EXPERIMENTAL
Intervention: Positive Technology Application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29942346

Group type: EXPERIMENTAL
Intervention: BE FIT program
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 66
Study: 29942424

Group type: EXPERIMENTAL
Intervention: Novel Noninvasive Ultrasound Body Sculpting Device
Number of subjects: 0
Study: 29942422

Group type: EXPERIMENTAL
Intervention: Nonalcoholic Fatty Liver Disease (NAFLD) prevalence among psoriasis patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29942590

Group type: EXPERIMENTAL
Intervention: Mobile health intervention using the Social Pounds Off Digitally (POD) app.
Number of subjects: 0
Study: 29942591

Group type: EXPERIMENTAL
Intervention: Self-guided E-Couch social anxiety module
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 0
Study: 29942666

Group type: EXPERIMENTAL
Intervention: FOLFOX/D/T (FOLFOX plus durvalumab and tremelimumab)
Number of subjects: 48

Group type: COMPARATOR
Intervention: FOLFOX (standard therapy)
Number of subjects: 48
Study: 29943666

Group type: EXPERIMENTAL
Intervention: PVSRIPO (recombinant nonpathogenic polio-rhinovirus chimera)
Number of subjects: 61
Study: 29943734

Group type: EXPERIMENTAL
Intervention: hsPDA (hemodynamically significant patent ductus arteriosus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closed ductus arteriosus (DA)
Number of subjects: 0
Study: 29944518

Group type: EXPERIMENTAL
Intervention: Intravenous iron (IVI) treatment with ferric carboxymaltose (500-1000 mg)
Number of subjects: 1101

Group type: COMPARATOR
Intervention: No intravenous iron (IVI) treatment
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Intravenous iron (IVI) treatment
Number of subjects: 1101

Group type: COMPARATOR
Intervention: Intravenous iron (IVI) treatment and no IVI treatment
Number of subjects: 1101

Group type: COMPARATOR
Intervention: Anemia
Number of subjects: 1101
Study: 29944678

Group type: EXPERIMENTAL
Intervention: HIV-positive participants with CD4>500
Number of subjects: 11500

Group type: EXPERIMENTAL
Intervention: HIV-positive participants with CD4 351-500
Number of subjects: 11500

Group type: EXPERIMENTAL
Intervention: HIV-positive participants with CD4 ≤350
Number of subjects: 11500

Group type: EXPERIMENTAL
Intervention: HIV-negative participants residing with a CD4>500 HIV-positive person
Number of subjects: 11500

Group type: EXPERIMENTAL
Intervention: HIV-negative participants residing with an HIV-positive person with CD4 351-500
Number of subjects: 11500

Group type: EXPERIMENTAL
Intervention: HIV-negative participants residing with a household member with CD4 ≤350
Number of subjects: 11500

Group type: EXPERIMENTAL
Intervention: HIV-positive participants in all CD4 categories
Number of subjects: 11500
Study: 29944728

Group type: EXPERIMENTAL
Intervention: Hybrid Capture 2 (HC2; Qiagen)
Number of subjects: 4168

Group type: EXPERIMENTAL
Intervention: Aptima (Hologic)
Number of subjects: 4168

Group type: EXPERIMENTAL
Intervention: PreservCyt medium (Hologic) with HC2
Number of subjects: 4168

Group type: COMPARATOR
Intervention: Aptima or Cobas 4800 (Roche Diagnostics) with PreservCyt
Number of subjects: 4168
Study: 29945604

Group type: EXPERIMENTAL
Intervention: School doctors' routine health checks
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Study questionnaires filled by parents, nurses, and teachers
Number of subjects: 1050
Study: 29945630

Group type: EXPERIMENTAL
Intervention: Certified service or hearing dogs
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Physical service dogs
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Diabetes alert dogs
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 55
Study: 29945631

Group type: EXPERIMENTAL
Intervention: Multi-component Sickle Cell Disease Implementation Consortium (SCDIC) interventions
Number of subjects: 0
Study: 29945633

Group type: EXPERIMENTAL
Intervention: Lognormal approach for analyzing postpartum blood loss
Number of subjects: 0
Study: 29945645

Group type: EXPERIMENTAL
Intervention: Miscarriage between 6 and 8 weeks gestation
Number of subjects: 30166

Group type: EXPERIMENTAL
Intervention: Miscarriage between 8 and 12 weeks gestation
Number of subjects: 30166

Group type: EXPERIMENTAL
Intervention: Miscarriage between 12 and 20 weeks gestation
Number of subjects: 30166

Group type: EXPERIMENTAL
Intervention: Medically terminated pregnancy (MTP) between 6 and 8 weeks gestation
Number of subjects: 30166

Group type: EXPERIMENTAL
Intervention: Medically terminated pregnancy (MTP) between 8 and 12 weeks gestation
Number of subjects: 30166

Group type: EXPERIMENTAL
Intervention: Medically terminated pregnancy (MTP) between 12 and 20 weeks gestation
Number of subjects: 30166

Group type: EXPERIMENTAL
Intervention: Stillbirth rate
Number of subjects: 30166

Group type: EXPERIMENTAL
Intervention: Neonatal mortality rate
Number of subjects: 30166

Group type: EXPERIMENTAL
Intervention: Living infant at 28 days of age
Number of subjects: 30166

Group type: EXPERIMENTAL
Intervention: Risk factors for miscarriage and MTP
Number of subjects: 30166
Study: 29945647

Group type: EXPERIMENTAL
Intervention: Population-based pregnancy outcome registry
Number of subjects: 427111

Group type: COMPARATOR
Intervention: No prenatal care
Number of subjects: 427111

Group type: COMPARATOR
Intervention: Zero parity and parity > 3
Number of subjects: 427111

Group type: COMPARATOR
Intervention: Maternal age < 20 years and age > 35 years
Number of subjects: 427111
Study: 29945651

Group type: EXPERIMENTAL
Intervention: Research tests for infection and other conditions, standard autopsy, and minimally invasive tissue sampling conducted on stillbirths and preterm neonates who die ≤ 28 days.
Number of subjects: 0
Study: 29945665

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate availability in public facilities
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate availability in private facilities
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Usage of magnesium sulphate for severe pre-eclampsia
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Non-usage of magnesium sulphate for eclampsia
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Stock outs of magnesium sulphate
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Formulations of magnesium sulphate
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Recommendations for improving magnesium sulphate use
Number of subjects: 88
Study: 29945738

Group type: COMPARATOR
Intervention: Montelukast (10 mg/day)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg/day) / Levocetirizine (5 mg/day)
Number of subjects: 228
Study: 29945859

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) social network during awake craniotomy
Number of subjects: 3
Study: 29945861

Group type: EXPERIMENTAL
Intervention: Young with Diabetes app
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study: 29945907

Group type: EXPERIMENTAL
Intervention: Visual inspection of pressure-time curve by trained clinicians
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Visual inspection of pressure-time curve to distinguish downward concavity from linear shape
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Visual inspection of pressure-time curve to distinguish upward concavity from linear shape
Number of subjects: 36

Group type: COMPARATOR
Intervention: Quantitative analysis of SI using specific research software (reference method)
Number of subjects: 36
Study: 29946005

Group type: EXPERIMENTAL
Intervention: Nintedanib added to pirfenidone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pirfenidone (1602-2403 mg·day)
Number of subjects: 0
Study: 29946013

Group type: EXPERIMENTAL
Intervention: Packed red blood cell transfusion
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Hemoglobin concentration >10 g/dL
Number of subjects: 413

Group type: COMPARATOR
Intervention: Anemia after aneurysm securing
Number of subjects: 413

Group type: COMPARATOR
Intervention: Anemia during delayed cerebral ischemia window
Number of subjects: 413
Study: 29946297

Group type: EXPERIMENTAL
Intervention: Chronic insufficient sleep (1:2 sleep:wake ratio, 6.67 hours sleep:13.33 hours wake)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (1:2 sleep:wake ratio, 6.67 hours sleep:13.33 hours wake)
Number of subjects: 0
Study: 29946480

Group type: EXPERIMENTAL
Intervention: Pilot study intervention
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Secondary exploratory clinical outcomes
Number of subjects: 250
Study: 29946558

Group type: EXPERIMENTAL
Intervention: Multipolar pacing (MPP)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Best BiV pacing (BestBiV)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Multisite pacing (MPP and MVP)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Multisite pacing (MVP)
Number of subjects: 24
Study: 29946683

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 694

Group type: COMPARATOR
Intervention: Nevirapine
Number of subjects: 694
Study: 29946946

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) patients with varying AHI levels
Number of subjects: 101

Group type: COMPARATOR
Intervention: Healthy older subjects without OSA (AHI < 15)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Older subjects with incident hypertension
Number of subjects: 101
Study: 29947727

Group type: EXPERIMENTAL
Intervention: Not applicable (observational study)
Number of subjects: 129276
Study: 29947745

Group type: EXPERIMENTAL
Intervention: Childhood sexual abuse
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Emotional abuse
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Emotional neglect
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Inconsistency experiences
Number of subjects: 421

Group type: COMPARATOR
Intervention: Physical abuse/neglect
Number of subjects: 421

Group type: COMPARATOR
Intervention: Violence against the mother
Number of subjects: 421

Group type: COMPARATOR
Intervention: Drug abuse in the family
Number of subjects: 421

Group type: COMPARATOR
Intervention: Mentally handicapped family members
Number of subjects: 421

Group type: COMPARATOR
Intervention: Suicidal intentions in the family
Number of subjects: 421

Group type: COMPARATOR
Intervention: Family members in prison
Number of subjects: 421
Study: 29947766

Group type: EXPERIMENTAL
Intervention: Endometriosis
Number of subjects: 1120

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1120
Study: 29947806

Group type: EXPERIMENTAL
Intervention: Maternal serum cobalamin concentration at week 18 of pregnancy
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Plasma total homocysteine (tHcy) levels
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Plasma methylmalonic acid (MMA) levels
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Maternal serum cobalamin concentration <394 pmol/L at week 18
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Correlation of maternal serum cobalamin concentration with infant serum cobalamin concentration
Number of subjects: 114
Study: 29948106

Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Consecutive PET/CTs
Number of subjects: 68
Study: 29948165

Group type: EXPERIMENTAL
Intervention: Linear array ultrasound measurement of LUS-muscular thickness
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Curved array ultrasound measurement of LUS-muscular thickness
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound measurement of LUS-muscular thickness
Number of subjects: 33
Study: 29948233

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment (CBT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Educational play group (control)
Number of subjects: 81
Study: 29948286

Group type: EXPERIMENTAL
Intervention: Sustained atrial fibrillation (AF)
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: Concomitant heart failure (HF) with sustained AF
Number of subjects: 1089
Study: 29948299

Group type: EXPERIMENTAL
Intervention: Giant cavernous carotid aneurysms with lateral mass effect
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Giant cavernous carotid aneurysms with mixed medial/lateral mass effect
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Giant cavernous carotid aneurysms with medial mass effect
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Presence of partial thrombosis (PT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Aneurysm volume
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Occurrence of PT
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Patient age
Number of subjects: 34
Study: 29948356

Group type: EXPERIMENTAL
Intervention: Sonidegib plus docetaxel (fixed dose at 75 mg/m2)
Number of subjects: 0
Study: 29948397

Group type: EXPERIMENTAL
Intervention: eSNAP (electronic Social Network Assessment Program)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study: 29948566

Group type: EXPERIMENTAL
Intervention: Once-daily PPI therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice-daily PPI therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin/NSAID use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemoprevention after mucosal ablation
Number of subjects: 0
Study: 29948766

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 8
Study: 29949102

Group type: EXPERIMENTAL
Intervention: Verinurad 15 mg administered orally under fasted conditions
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (normal renal function)
Number of subjects: 8
Study: 29949132

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg BID
Number of subjects: 199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg BID in LTE study
Number of subjects: 199
Study: 29949718

Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) in severe COPD patients
Number of subjects: 1794

Group type: COMPARATOR
Intervention: Control subjects with normal pulmonary function
Number of subjects: 1794
Study: 29950123

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C (Pascorbin®; Pascoe, Giessen, Germany)
Number of subjects: 71
Study: 29950349

Group type: EXPERIMENTAL
Intervention: Intratumoral Poly-ICLC
Number of subjects: 0
Study: 29950463

Group type: EXPERIMENTAL
Intervention: Natural corollaries and recovery after ACL injury (no specific intervention mentioned)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: ACL reconstruction (for participants who have surgical treatment)
Number of subjects: 130
Study: 29950464

Group type: EXPERIMENTAL
Intervention: Cauterisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fibrin glue
Number of subjects: 0
Study: 29950465

Group type: EXPERIMENTAL
Intervention: Real-time audio-visual feedback on TSD to caregivers via premounted handhelds and tablets
Number of subjects: 300
Study: 29950475

Group type: EXPERIMENTAL
Intervention: Exenatide (add-on treatment to insulin therapy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 100
Study: 29950480

Group type: EXPERIMENTAL
Intervention: Multimodal computerised decision support system (CDSS) integrated in the electronic health record (EHR)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard-of-care antimicrobial stewardship (AMS)
Number of subjects: 24
Study: 29950693

Group type: EXPERIMENTAL
Intervention: Total CK18 (tCK18)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Apoptotic CK18 fragments (CK18F)
Number of subjects: 109
Study: 29951525

Group type: EXPERIMENTAL
Intervention: Right Ventricular Apical (RVA) pacing
Number of subjects: 437

Group type: COMPARATOR
Intervention: Non-RVA pacing
Number of subjects: 437
Study: 29951599

Group type: EXPERIMENTAL
Intervention: Ultrasonic scissors
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Conventional haemostasis
Number of subjects: 1329
Study: 29951631

Group type: EXPERIMENTAL
Intervention: Anodal tDCS for 20 min during training
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham stimulation for 20 min during training
Number of subjects: 40
Study: 29951634

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study: 29951694

Group type: EXPERIMENTAL
Intervention: Belinostat (48-h continuous intravenous infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher belinostat drug exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: q3week schedule of belinostat infusion
Number of subjects: 0
Study: 29951750

Group type: EXPERIMENTAL
Intervention: Multifaceted individualized pneumoperitoneum strategy (ventilation with low tidal volume, modified lithotomy position, deep neuromuscular blockade, pre-stretching of the abdominal wall, individualized intra-abdominal pressure titration)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Multifaceted individualized pneumoperitoneum strategy
Number of subjects: 92
Study: 29951977

Group type: EXPERIMENTAL
Intervention: Pregabalin (stepwise dose escalation from 75 mg to 600 mg daily)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 27
Study: 29952243

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29952802

Group type: EXPERIMENTAL
Intervention: Shear-mediated platelet activation (SMPA) quantified via the Platelet Activity State (PAS) assay before and after pump exchange and heart transplantation.
Number of subjects: 1
Study: 29952895

Group type: EXPERIMENTAL
Intervention: Internal fixation (n = 11)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment (n = 6)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Surgical randomization (n = 13)
Number of subjects: 30
Study: 29953745

Group type: EXPERIMENTAL
Intervention: Muscle co-activation during stair ascent
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Muscle combinations within the same activity
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Comparison of muscle co-activation between activities
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Mediolateral muscle co-activation
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Muscle co-activation strategies during activities of daily living
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Muscle co-activation during challenging activities
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Role of mediolateral vs hamstrings/quadriceps co-activation
Number of subjects: 77
Study: 29954008

Group type: EXPERIMENTAL
Intervention: Novel classification system using peroral cholangioscopy (POCS) for bile duct lesions
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Expert observers
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Non-expert observers
Number of subjects: 171
Study: 29954415

Group type: EXPERIMENTAL
Intervention: Bortezomib and rituximab maintenance therapy
Number of subjects: 23
Study: 29954418

Group type: EXPERIMENTAL
Intervention: search and destroy (SD) strategy, a quick and short, systemic antibiotic treatment
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: continuous suppression (CS) strategy, a repeated chronic topical antibiotic treatment
Number of subjects: 138

Group type: COMPARATOR
Intervention: search and destroy (SD) strategy
Number of subjects: 138

Group type: COMPARATOR
Intervention: continuous suppression (CS) strategy
Number of subjects: 138
Study: 29954605

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate clamping
Number of subjects: 0
Study: 29954728

Group type: EXPERIMENTAL
Intervention: Cardiogenic Shock team intervention (early multidisciplinary team activation, rapid initiation of mechanical circulatory support, hemodynamic-guided management)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Cardiogenic Shock team intervention
Number of subjects: 250

Group type: COMPARATOR
Intervention: Historical controls (2015 and 2016)
Number of subjects: 250
Study: 29954744

Group type: EXPERIMENTAL
Intervention: MINOCA
Number of subjects: 2690

Group type: COMPARATOR
Intervention: MI-CAD
Number of subjects: 2690
Study: 29954840

Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Functional experiments in GBC cell lines
Number of subjects: 157
Study: 29954877

Group type: EXPERIMENTAL
Intervention: Low-cost sexual health prevention strategies such as condoms
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Strategies to eroticise male and female condoms
Number of subjects: 21